


UBS Future of Humans

Performance **Review**

Multi Manager Access II - Future of Humans USD F-UKdist



Performance (basis USD, net of fees)¹



Past performance is not a reliable indicator of future results.

Performance in % (net of fees)¹

in %	2019	2020	2021	2022	2023 YTD ²	LTD ³	2 years Ø p.a.	2 years
Fund (USD)	n.a.	n.a.	5.55	-25.74	5.45	-10.19	-17.76	-9.31
Ref. Index ⁴	n.a.	n.a.	18.54	-18.36	7.17	16.10	4.18	2.07

The performance shown does not take account of any commissions, entry or exit charges.

¹ These figures refer to the past. If the currency of a financial product, financial service or its costs is different from your reference currency, the return and/or costs can increase or decrease as a result of currency fluctuations. Source for all data and chart (if not indicated otherwise): UBS Asset Management.

² YTD: year-to-date (since beginning of the year)

³ LTD: launch-to-date

⁴ Reference Index in currency of share class (without costs)

After a bleak 2022, the new year is off to a good start with global stocks delivering strong returns. Gains this month were primarily led by optimism surrounding China's reopening, as well as improved sentiment towards the eurozone after a mild winter helped to avert a major energy shortage.

Monthly performance

In January the fund performed positively with 5.5%. Performance was supported by the consumer experience theme, while the longevity and health themes detracted.

YTD performance

YTD as of the end of January, the fund has delivered a positive performance of 5.5%. Please refer to the monthly performance comments above.

Performance contributors

The fund benefited from holding Amazon, which performed well following weakness in December. Amazon announced that it is adding a delivery fee for Amazon Fresh deliveries for baskets under USD 150 in an effort to drive basket prices higher. The company has also announced significant cuts to headcount.

Performance detractors

An active position in PowerSchool Holdings weighed on performance due to the firm targeting more defensive end markets (pre-K-12), which lagged the rebound in higher-growth tech companies.

For more information

Internet: www.ubs.com/luxembourgfunds

Contact your client advisor

UBS Future of Humans

Sector exposure (%)

	Fund	Index
Health Care	56.69	12.46
Financials	12.75	15.30
Information Technology	9.03	20.61
Consumer Discretionary	8.20	11.13
Communication Services	4.58	7.14
Industrials	3.50	9.99
Consumer Staples	2.75	7.33
Real Estate	2.51	2.63
Materials	0.00	5.11
Others	-0.01	8.30

10 largest equity positions (%)

	Fund	Index
Eli Lilly & Co	3.03	0.46
UnitedHealth Group Inc	2.87	0.78
Novo Nordisk A/S	2.85	0.38
Boston Scientific Corp	2.51	0.11
AIA Group Ltd	2.37	0.22
Abbott Laboratories	2.24	0.32
Danaher Corp	2.12	0.30
Prudential PLC	2.12	0.08
Roche Holding AG	1.92	0.36
Humana Inc	1.90	0.11

Market exposure (%)

	Fund	Deviation from index
United States	65.83	+5.8
Switzerland	6.56	+4.0
United Kingdom	4.83	+1.0
China	4.06	+0.3
Hong Kong	3.54	+2.8
France	3.45	+0.3
Denmark	3.37	+2.7
Japan	1.31	-4.2
Australia	1.29	-0.8
Canada	1.10	-2.0
Others	4.66	-9.9

Investment managers and Strategy

Invesco - Consumer preferences	12.68
Newton - Longevity	51.60
UBS AM - Health	21.39
Wellington - Education	14.33

Please note that additional fees (e.g. entry or exit fees) may be charged. Please refer to your financial adviser for more details. Investors should read the Key Investor Information Document (KIID), Prospectus and any applicable local offering document prior to investing and to get complete information of the risks. Investors are acquiring units or shares in a fund, and not in a given underlying asset such as building or shares of a company. For a definition of financial terms refer to the glossary available at www.ubs.com/am-glossary.

For marketing and information purposes by UBS. UBS funds under Luxembourg law. Arrangements for marketing fund units mentioned in this document may be terminated at the initiative of the management company of the fund(s). Representative in Switzerland for UBS funds established under foreign law: UBS Fund Management (Switzerland) AG, P.O. Box, CH-4002 Basel. Paying agent: UBS Switzerland AG, Bahnhofstrasse 45, CH-8001 Zurich. Prospectuses, key information document, the articles of association or the management regulations as well as annual and semi-annual reports of UBS funds are available in a language required by the local applicable law free of charge from UBS Asset Management Switzerland AG, c/o UBS AG, Bahnhofstrasse 45, 8001 Zürich, Switzerland or from UBS Fund Management (Switzerland) AG, P.O. Box, CH-4002 Basel. The product described herein aligns to Article 6 Regulation (EU) 2019/2088 on sustainability-related disclosures in the financial services sector. Information on sustainability-related aspects pursuant to that regulation can be found on www.ubs.com/funds. The benchmark is the intellectual property of the respective index provider. The fund or the share class is neither sponsored nor endorsed by the index provider. The fund prospectus or supplemental prospectus contains the full disclaimer. Before investing in a product please read the latest prospectus and key information document carefully and thoroughly. Any decision to invest should take into account all the characteristics or objectives of the fund as described in its prospectus, or similar legal documentation. Investors are acquiring units or shares in a fund, and not in a given underlying asset such as building or shares of a company. The information and opinions contained in this document have been compiled or arrived at based upon information obtained from sources believed to be reliable and in good faith, but is not guaranteed as being accurate, nor is it a complete statement or summary of the securities, markets or developments referred to in the document. Members of the UBS Group may have a position in and may make a purchase and / or sale of any of the securities or other financial instruments mentioned in this document. Units of UBS funds mentioned herein may not be eligible for sale in all jurisdictions or to certain categories of investors and may not be offered, sold or delivered in the United States. The information mentioned herein is not intended to be construed as a solicitation or an offer to buy or sell any securities or related financial instruments. Past performance is not a reliable indicator of future results. The performance shown does not take account of any commissions and costs charged when subscribing to and redeeming units. If whole or part of the total costs to be paid is different from your reference currency, the costs may increase or decrease as a result of currency and exchange rate fluctuations. Commissions and costs have a negative impact on the investment and on the expected returns. If the currency of a financial product or financial service is different from your reference currency, the return can increase or decrease as a result of currency and exchange rate fluctuations. This information pays no regard to the specific or future investment objectives, financial or tax situation or particular needs of any specific recipient. Future performance is subject to taxation which depends on the personal situation of each investor and which may change in the future. The details and opinions contained in this document are provided by UBS without any guarantee or warranty and are for the recipient's personal use and information purposes only. This document may not be reproduced, redistributed or republished for any purpose without the written permission of UBS Asset Management Switzerland AG or a local affiliated company. Source for all data and charts (if not indicated otherwise): UBS Asset Management. This document contains statements that constitute "forward-looking statements", including, but not limited to, statements relating to our future business development. While these forward-looking statements represent our judgments and future expectations concerning the development of our business, a number of risks, uncertainties and other important factors could cause actual developments and results to differ materially from our expectations. A summary of investor rights in English can be found online at www.ubs.com/ funds. More explanations of financial terms can be found at www.ubs.com/am-glossary.

© UBS 2023. The key symbol and UBS are among the registered and unregistered trademarks of UBS. All rights reserved.

Current investment strategy

The strategy is focused on the bottom-up stock selection of companies that benefit from long-term thematic trends. The fund's largest positions are in companies exposed to longevity, education, healthcare and consumer preferences.

Risks

A new fund with no track record, notwithstanding the investment history of the portfolio managers.

An equity fund with exposure to emerging economies and to small, growing and innovative companies which can result in significant fluctuations in value, particularly in the short term. The thematic focus may lead to concentrations in a specific sector.

The performance of actively managed funds may deviate significantly from the referenced index.

The fund can use derivatives, which may result in additional counterparty and liquidity risks.